Cargando…

The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer

OBJECTIVE: Metaplastic breast cancer (MpBC) is an aggressive subtype of all breast cancer. We aimed to investigate the clinicopathological features, treatments and prognoses of MpBC patients. METHODS: We collected the data from MpBC patients diagnosed at Tianjin Medical University Cancer Hospital fr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiayue, Lang, Ronggang, Zhao, Weipeng, Jia, Yongsheng, Tong, Zhongsheng, Shi, Yehui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224839/
https://www.ncbi.nlm.nih.gov/pubmed/37160814
http://dx.doi.org/10.1007/s10549-023-06945-9
_version_ 1785050283216207872
author Hu, Jiayue
Lang, Ronggang
Zhao, Weipeng
Jia, Yongsheng
Tong, Zhongsheng
Shi, Yehui
author_facet Hu, Jiayue
Lang, Ronggang
Zhao, Weipeng
Jia, Yongsheng
Tong, Zhongsheng
Shi, Yehui
author_sort Hu, Jiayue
collection PubMed
description OBJECTIVE: Metaplastic breast cancer (MpBC) is an aggressive subtype of all breast cancer. We aimed to investigate the clinicopathological features, treatments and prognoses of MpBC patients. METHODS: We collected the data from MpBC patients diagnosed at Tianjin Medical University Cancer Hospital from 2010 to 2017. Kaplan Meier curves and Cox regression model were used to evaluating clinical outcomes and prognostic factors. After removing baseline differences by propensity score matching (PSM), we analyzed the prognosis between MpBC patients and invasive ductal carcinomas of no special type (IDC-NST) patients. RESULTS: A total of 217 MpBC patients were subsumed. Of all histological subtypes, 45.1% were mixed subtypes, followed by with mesenchymal differentiation (27.2%), pure squamous (15.2%) and pure spindle (12.4%) subtypes. 69.6% of MpBC were triple-negative, 25.3% and 6.5% were HR-positive and HER2-positive. MpBC patients had worse survival compared to IDC-NST patients, with 5-year RFS of 73.8 and 83.6% (HR = 1.177 95%CI (1.171–2.676) P = 0.0068), and 5-year BCSS of 79.0% and 89.7% (HR = 2.187 95%CI (1.357–3.523) P = 0.0013). In the multivariate COX model, AJCC stage, mixed subtype and chemotherapy were independent prognostic factors. Mixed MpBC is more aggressive than pure and with heterologous mesenchymal differentiation subtypes. And whether squamous or spindle MpBC, mixed forms have shorter outcomes than pure forms. CONCLUSIONS: MpBCs are associated with poorer prognoses than IDC-NSTs. They are heterogeneous with different clinicopathological features and clinical outcomes between histological subtypes. Pure and with heterologous mesenchymal differentiation subtypes have more survival benefits than the mixed subtype.
format Online
Article
Text
id pubmed-10224839
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-102248392023-05-29 The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer Hu, Jiayue Lang, Ronggang Zhao, Weipeng Jia, Yongsheng Tong, Zhongsheng Shi, Yehui Breast Cancer Res Treat Preclinical Study OBJECTIVE: Metaplastic breast cancer (MpBC) is an aggressive subtype of all breast cancer. We aimed to investigate the clinicopathological features, treatments and prognoses of MpBC patients. METHODS: We collected the data from MpBC patients diagnosed at Tianjin Medical University Cancer Hospital from 2010 to 2017. Kaplan Meier curves and Cox regression model were used to evaluating clinical outcomes and prognostic factors. After removing baseline differences by propensity score matching (PSM), we analyzed the prognosis between MpBC patients and invasive ductal carcinomas of no special type (IDC-NST) patients. RESULTS: A total of 217 MpBC patients were subsumed. Of all histological subtypes, 45.1% were mixed subtypes, followed by with mesenchymal differentiation (27.2%), pure squamous (15.2%) and pure spindle (12.4%) subtypes. 69.6% of MpBC were triple-negative, 25.3% and 6.5% were HR-positive and HER2-positive. MpBC patients had worse survival compared to IDC-NST patients, with 5-year RFS of 73.8 and 83.6% (HR = 1.177 95%CI (1.171–2.676) P = 0.0068), and 5-year BCSS of 79.0% and 89.7% (HR = 2.187 95%CI (1.357–3.523) P = 0.0013). In the multivariate COX model, AJCC stage, mixed subtype and chemotherapy were independent prognostic factors. Mixed MpBC is more aggressive than pure and with heterologous mesenchymal differentiation subtypes. And whether squamous or spindle MpBC, mixed forms have shorter outcomes than pure forms. CONCLUSIONS: MpBCs are associated with poorer prognoses than IDC-NSTs. They are heterogeneous with different clinicopathological features and clinical outcomes between histological subtypes. Pure and with heterologous mesenchymal differentiation subtypes have more survival benefits than the mixed subtype. Springer US 2023-05-09 2023 /pmc/articles/PMC10224839/ /pubmed/37160814 http://dx.doi.org/10.1007/s10549-023-06945-9 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Preclinical Study
Hu, Jiayue
Lang, Ronggang
Zhao, Weipeng
Jia, Yongsheng
Tong, Zhongsheng
Shi, Yehui
The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
title The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
title_full The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
title_fullStr The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
title_full_unstemmed The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
title_short The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
title_sort mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
topic Preclinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10224839/
https://www.ncbi.nlm.nih.gov/pubmed/37160814
http://dx.doi.org/10.1007/s10549-023-06945-9
work_keys_str_mv AT hujiayue themixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT langronggang themixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT zhaoweipeng themixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT jiayongsheng themixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT tongzhongsheng themixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT shiyehui themixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT hujiayue mixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT langronggang mixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT zhaoweipeng mixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT jiayongsheng mixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT tongzhongsheng mixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer
AT shiyehui mixedsubtypehasaworseprognosisthanotherhistologicalsubtypesaretrospectiveanalysisof217patientswithmetaplasticbreastcancer